Archer Materials (ASX:AXE) has made progress in its development of biochip technology, having developed software and incorporated hardware with its biochip platform.
Archer Materials says it addresses a fundamental phenomenon that limits graphene field effect transistors (gFET) device sensitivity.
It also says the innovation allows for the selective, complex on-chip detection of target biomolecules with increased sensitivity compared to static cases.
With the incorporation of atom-thin graphene, Archer Materials says it can develop advanced semiconductor devices for quantum computing and medical diagnostics.